Repare Therapeutics Inc.
Repare Therapeutics Inc. (RPTX): 12 pipeline candidates · ~25 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
24.7 months
D/E 0.10 · 0% dilution
Lead: Phase 2
12 candidates
N/A
N/A
A transparent, data-derived signal for Repare Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$114.2M
Cash
$72.8M
Quarterly Burn
$13.9M
Runway
24.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| Camonsertib (RP-3500) | Phase 2 |
| FOLFIRI Protocol | Phase 2 |
| lunre+camo | — |
| Lunresertib (RP-6306) | Phase 2 |
| Olaparib | Phase 1 |
| Olaparib 200-300 mg BID, daily | Phase 1 |
| RP-1664 | Phase 2 |
| RP-3467 | Phase 2 |
| RP-3467 at assigned dose and schedule | Phase 1 |
| RP-3500 | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Repare Therapeutics Inc.'s pipeline?
Repare Therapeutics Inc. (RPTX) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Repare Therapeutics Inc.'s lead drug candidate?
Repare Therapeutics Inc.'s most advanced tracked candidate is Camonsertib (RP-3500) (Phase 2) for Solid Tumor; Chronic Lymphocytic Leukemia; Advanced Cancer.
What is Repare Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Repare Therapeutics Inc. has approximately 24.7 months of cash runway.
What is Repare Therapeutics Inc.'s market capitalization?
Repare Therapeutics Inc.'s market capitalization is approximately $114.2M.
Who is the CEO of Repare Therapeutics Inc.?
Mr. Steve Forte CPA is the chief executive officer of Repare Therapeutics Inc. (RPTX).
Get the full picture on Repare Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.